A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

This is a Phase I, randomised, single-blind, placebo-controlled, single-centre study. This study comprises upto a total of 42 subjects. This study consists of two parts: A single dose part (Part A1 and Part A2) and a multiple dose part (Part B). Part A and Part B will comprise of the following: * Each subject will be involved in the study for up to 9 weeks if enrolled in Part A and up to 10 weeks if enrolled in Part B. * A screening period of maximum 28 days. * Treatment period: Part A: Study treatment Day 1; Part B: Study treatment Days 1 to 6 and a single inhaled dose on Day 7. * A safety follow-up call will be conducted 7 (± 1) days after elarekibep or placebo administration. * A safety follow-up visit will be conducted 30 (± 2) days after elarekibep or placebo administration in each cohort.